Pieris Pharmaceuticals to Present at Investor Conferences in November
November 08, 2018 08:00 ET
|
Pieris Pharmaceuticals, Inc.
BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 07, 2018 07:00 ET
|
Pieris Pharmaceuticals, Inc.
Company to Host an Investor Conference Call on Wednesday, November 7, 2018 at 8:00 AM EST BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage...
Pieris Pharmaceuticals to Host Third Quarter 2018 Investor Call and Corporate Update on November 7, 2018
October 31, 2018 08:00 ET
|
Pieris Pharmaceuticals, Inc.
BOSTON, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform...
Pieris Pharmaceuticals Appoints Matthew L. Sherman, M.D., to its Board of Directors
October 25, 2018 08:16 ET
|
Pieris Pharmaceuticals, Inc.
BOSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/ONC0055 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 02, 2018 08:00 ET
|
Pieris Pharmaceuticals, Inc.
BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
Pieris Pharmaceuticals to Present at Investor Conferences in October
September 25, 2018 08:00 ET
|
Pieris Pharmaceuticals, Inc.
BOSTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
Pieris Pharmaceuticals to Present Preclinical Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the ERS International Congress 2018
September 14, 2018 08:00 ET
|
Pieris Pharmaceuticals, Inc.
BOSTON, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. to its Board of Directors
September 10, 2018 08:00 ET
|
Pieris Pharmaceuticals, Inc.
BOSTON, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
September 04, 2018 08:00 ET
|
Pieris Pharmaceuticals, Inc.
BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform...
Pieris Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 30, 2018 08:00 ET
|
Pieris Pharmaceuticals, Inc.
BOSTON, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform...